Clinitech Laboratory Limited is a Healthcare Services company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 9 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 1.83 |
| ROE % · ROCE % | — · 6.6 |
| Debt / equity (x) | — |
| Cash from operations | (1) |
| Capex | (1) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 4 |
| Profit before tax | 0 |
| Net profit | — |
| EPS (₹) | 0.52 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 24 Aug 2026 · Clinitech Laboratory fixes AGM on Sep 24, 2026 via video conferencing | compliance | minimal | — | — |
| 22 Aug 2026 · Notice of 16th AGM on September 24, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Clinitech Lab 16th AGM on Sep 24, 2026; book closure Sep 18 to 24 | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Clinitech Lab files FY26 Annual Report; AGM set for Sept 24 | results | medium | — | — |
| 17 Aug 2026 · Board approves FY26 report, fixes 16th AGM date and book closure dates | management changes | low | — | — |
| 12 Aug 2026 · Board meeting on Aug 17 to approve AGM notice and Board report | board shareholder meetings | low | — | — |
| 7 Jul 2026 · RTA confirms Reg 74(5) compliance; all shares held in demat form | compliance | minimal | — | — |
| 28 May 2026 · Statement disclosing no deviation and Variation from object of issue as on March 31, 2026 | compliance | minimal | — | — |
| 28 May 2026 · Outcome of Board meeting held today i.e May 28, 2026 through video conferencing at 02.30 P.M for approval of Audited Financial Results for the half year and financial year ended March 31, 2026 | results | high | — | — |
| 28 May 2026 · With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e., on May, .... | results | medium | — | — |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 67.5 | 23.2 | 24 of 29 | 18% |
| ROCE | 5.9 | 6.1 | 16 of 29 | 46% |
| Market cap | 8 | 38 | 26 of 30 | 14% |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
